ZHZhonglin Hu

Zhonglin Hu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Zhonglin Hu has a total of 17 co-authors. Here are the top co-authors by number of shared publications:

  • Haona Xv

    Plastic surgery hospital Chinese Academy of Medical Sciences and Peking Union Medical College Beijing China

    2 shared publications
  • Lin Lin

    Ear Reconstruction Center, Plastic Surgery Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China

    2 shared publications
  • Senmao Wang

    Plastic surgery hospital Chinese Academy of Medical Sciences and Peking Union Medical College Beijing China

    2 shared publications
  • Aiping Feng

    Peking Union Medical College Hospital

    1 shared publication
  • Baozhen Shan

    Plastic surgery hospital Chinese Academy of Medical Sciences and Peking Union Medical College Beijing China

    1 shared publication
  • Boyao Wan

    Department of Gastroenterology, Qilu Hospital of Shandong University, Cheeloo College of Medicine, Shandong University, Jinan, China

    1 shared publication

Latest Publications

  • Residual Orofacial-Cleft Burden After Incidence Adjustment is Not a Treatment-Gap Measure: A Methodological Examination of GBD 2023

    by Zhonglin Hu, Haona Xu, Leren He

    Global Burden of Disease (GBD) analyses of orofacial clefts often treat modeled disability-adjusted life-year (DALY) rates or quality-of-care indices as representing untreated disease or care quality. We tested whether an incidence-adjusted residual of GBD 2023 cleft estimates can support the reading for the craniofacial program targeting. Age-standardized estimates for 204 locations (1990–2023) were linked to World Bank indicators. The residual was the ordinary least squares remainder from a quadratic in year and World Bank region, fitted to log DALY rate on log incidence, using 6800 country-years (200 countries). The residual is not a validated measure of health-system or surgical access. A country-level age-matched residual could not be computed from the GBD country extract. Adding log incidence raised R 2 from 0.491 to 0.551 (incremental R 2 =0.060). The incidence coefficient was 0.723 (country-clustered 0.408–1.038; P =0.084 versus 1). In 2023, the SD of log incidence was 0.355 against 0.821 for log DALY rate, and 2.472 for log years of life lost (YLL) against 0.466 for log years lived with disability (YLD). Country order changed with grouping (Pearson r =0.62): Türkiye’s residual was 0.96 under World Bank Europe and Central Asia, versus −0.22 under GBD North Africa and the Middle East. The 2023 equal-country and population-weighted GDP gaps were 0.445 and 0.103 ( P =0.312). India held 49.1% of the poorest GDP quartile’s population. GBD-derived residuals should not be used as treatment-gap or surgical-access measures.

  • Costal cartilage segmentation with topology guided deformable mamba: Method and benchmark

    by Senmao Wang, Haifan Gong, Runmeng Cui, Boyao Wan, Zhonglin Hu, Haiqing Yang, Jingyang Zhou, Haiyue Jiang, Lin Lin

  • Open Access

    Efficacy and safety of platelet‐rich plasma in the treatment of venous ulcers: A systematic review and meta‐analysis of randomized controlled trials

    by Zhonglin Hu, Zhonglin Hu, Zhonglin Hu, Senmao Wang, Senmao Wang, Senmao Wang, Hao Yang, Hao Yang, Hao Yang, Haona Xv, et al.

    Considering the substantial impact of venous ulcers on quality of life and healthcare systems, this study evaluated the efficacy and safety of platelet‐rich plasma (PRP) in comparison to conventional therapy. A systematic review of four databases identified 16 randomized clinical trials, including 20 study groups. PRP significantly enhanced complete ulcer healing, exhibiting an odds ratio (OR) of 5.06 (95% confidence interval [CI]: 2.35–10.89), and increased the percentage of healed ulcer area by a mean difference of 47% (95% CI: 32%–62%). Additionally, PRP shortened the time required for complete healing by an average of 3.25 months (95% CI: −4.06 to −2.43). Although pain reduction was similar in both groups, PRP considerably decreased ulcer recurrence rates (OR = 0.16, 95% CI: 0.05–0.50) without increasing the risks of infection or irritative dermatitis. These results suggest PRP as a viable, safe alternative for venous ulcer treatment, providing significant improvements in healing outcomes.


  • Efficacy and Safety of Platelet-Rich Plasma for Pressure Ulcers: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

    by Zhonglin Hu, Haona Xv, Aiping Feng, Senmao Wang, Xuefeng Han

    Pressure ulcers are common chronic wounds in clinical practice, severely affecting patients’ quality of life and causing substantial economic burdens. Platelet-rich plasma (PRP) has been explored for its potential in treating pressure ulcers. Herein, a study was carried out to evaluate the efficacy and safety of PRP in comparison to conventional treatments for pressure ulcers. A comprehensive search was conducted in databases including PubMed, Embase, Web of Science, and Cochrane Library, covering studies published from the inception to May 20, 2023, with only randomized controlled trials (RCTs) assessing the effect of PRP on the healing of pressure ulcers included. The outcomes of interest included healing rates, ulcer area, ulcer volume, Pressure Ulcer Scale for Healing (PUSH) score, healing time, and complications. Finally, 9 RCTs, involving 511 patients with 523 pressure ulcers, met the inclusion criteria. Our meta-analysis revealed a significant improvement in the healing rate, as evidenced by a weighted odds ratio (OR) of 3.40 (95% CI = 1.87 to 6.21, I 2 = 32%, P < 0.0001). Additionally, the standard mean difference (SMD) for healed ulcer area favored the PRP group, reflecting an improvement of 1.38 cm 2 ( P = 0.02). Furthermore, the reduction in PUSH scores within the PRP group outperformed that observed in the control group, demonstrating a SMD of 1.69 ( P = 0.01). Nevertheless, complications and the SMD for ulcer volume reduction revealed no statistically significant differences between the groups. From these findings, PRP stands out as a promising and safe therapeutic approach for pressure ulcers. For a deeper understanding of PRP's role in pressure ulcer healing, it is crucial to conduct more well-structured, high-quality RCTs in upcoming studies.